Thyas has signed an exclusive license agreement with OncoTherapy Science Co., Ltd. (“OTS”; Kawasaki City, Kanagawa) to use OTS’s peptide vaccine for development, manufacturing and marketing of iPSC-derived T cell therapy for cancer treatment.